Cenix BioScience Establishes Flanders R&D Subsidiary

Cenix BioScience a leading contract research organisation specialising in RNA interference- (RNAi) and microRNA- (miRNA) -based drug discovery, is growing its R&D operations by establishing a new subsidiary in Flanders, Belgium.

Cenix BioScience BVBA, wholly owned by its Dresden-based parent, will help accelerate the company’s R&D capabilities in key growth areas including CNS-focused drug discovery and in vivo RNAi. This expansion comes as part of a major growth and diversification initiative ongoing since 2008 to broaden the company’s range of activities beyond the cell-based RNAi services that have established Cenix over the past 11 years.

“We are very excited to start this important new phase in our company’s development,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “This opportunity comes as the result of many years of hard work by past and present staff. It also arises at a particularly strategic time in the maturation of the RNAi field, which we are eager to help drive further forward in the years to come, now through both our original Dresden team and our new Flanders unit.”